b-TrCP E3 Ligase in CLL

Award Information
Agency:
Department of Health and Human Services
Amount:
$149,800.00
Program:
SBIR
Contract:
1R43CA119605-01
Solitcitation Year:
2006
Solicitation Number:
PHS2006-2
Branch:
N/A
Award Year:
2006
Phase:
Phase I
Agency Tracking Number:
CA119605
Solicitation Topic Code:
N/A
Small Business Information
PROGENRA, INC.
271A Great Valley Parkway, MALVERN, PA, 19355
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 BENJAMIN NICHOLSON
 (610) 644-6974
 nicholson@progenra.com
Business Contact
 MICHAEL MATTERN
Phone: (610) 644-6974
Email: MATTERN@PROGENRA.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): a-TrCP is a recently identified component of the SCF ubiquitin E3 ligase that purportedly targets multiple proteins for ubiquitination and degradation. Some of the demonstrated targets, such as I-?B and a-catenin, are members of signal transduction pathways that have been demonstrated to be relevant to the oncogenic process. In parallel, (a-TrCP has also been identified as playing an integral role in cancer as it is induced in human breast cancer cell lines and primary tumor samples. Further evidence suggests a role for (a-TrCP in tumor progression, as a-TrCP knockout mice are hypoplastic. Ablation of a-TrCP via siRNA or expression of a dominant negative mutant reverses the oncogenic potential as it effectively suppresses growth and survival of human breast cancer cell lines. The role that a-TrCP plays in NF-?B activation and tumor progression is direct. Upon specific activation signals, I-?B becomes phosphorylated and is then ubiquitinated by SCFa-TrCP and targeted for proteasomal degradation. Augmented NF-?B activity is detected in a host of tumor cell lines and primary tumors, including prostate, colon, lung, myelomas, leukemias, carcinomas, and neuroblastoma. With this constitutive NF-?B activity, many pro-survival factors, such as anti-apoptotic bcl-2 family members, and cell cycle regulators are expressed. An increase in SCFa-TrCP is hypothesized to contribute to the elevated levels of NF-?B activity and to tumor progression. In this proposed one year Phase I, a novel E3 ligase assay for a-TrCP will be configured for high throughput screening, with the aim of using this assay to discover novel antitumor drugs that act by inhibiting the cellular activity that would normally be facilitated by wild type a-TrCP. The ultimate commercial goal of the development of an assay for a-TrCP is to discover a drug with efficacy as a single agent or a component of conjoint therapy against a host of tumors in which there is constitutive NF-?B activity.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government